Top 15 Best-Selling Drugs of 2018
Top 15 Best-Selling Drugs of 2018
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
Τα νέα φάρμακα που θα κυκλοφορήσουν στην Ευρωπαϊκή Ένωση
Τα νέα φάρμακα που θα κυκλοφορήσουν στην Ευρωπαϊκή Ένωση
Το 25% των παγκόσμιων πωλήσεων στα φάρμακα θα έχει χαθεί μέχρι το 2023
Το 25% των παγκόσμιων πωλήσεων στα φάρμακα θα έχει χαθεί μέχρι το 2023
A Look at Miracle Drug Humira’s Journey to Proven Efficacy
A Look at Miracle Drug Humira’s Journey to Proven Efficacy
Drugmakers vie to capture slice of rheumatoid arthritis market
Drugmakers vie to capture slice of rheumatoid arthritis market
Pharm Exec’s 2019 Pipeline Report
Pharm Exec’s 2019 Pipeline Report
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
AbbVie staves off 6th Humira biosimilar in US
AbbVie staves off 6th Humira biosimilar in US
FDA Approves Humira Biosimilar That Won’t Be Available Until 2023
FDA Approves Humira Biosimilar That Won’t Be Available Until 2023
Moody’s picks 5 early winners in biosimilar market
Moody’s picks 5 early winners in biosimilar market
5th Humira biosimilar approved in EU as market entry nears
5th Humira biosimilar approved in EU as market entry nears
Ο ρόλος των βιο-ομοειδών στη Γαστρεντερολογία
Του Νίκου Βιάζη, Γαστρεντερολόγου-Διευθυντή του Γαστρεντερολογικού Τμήματος του ΓΝΑ «Ο Ευαγγελισμός» Από το 1998 –οπότε και το infliximab (Remicade) πήρε έγκριση για τη θεραπεία της νόσου Crohn–, οι βιολογικοί παράγοντες έχουν … Continue Reading Ο ρόλος των βιο-ομοειδών στη Γαστρεντερολογία
Top Pharma News of the Week
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
Five things to know about biosimilars right now
In the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart? With some of … Continue Reading Five things to know about biosimilars right now
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
As AbbVie Inc. continues to report Humira growth and investors continue to worry about biosimilar competition, the Chicago-area pharma offered a surprise when it presented its second quarter earnings: a better-than-expected performance for … Continue Reading AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
